Samsung Biologics Co.,Ltd. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was KRW 291,605.47 million compared to KRW 212,588.31 million a year ago. Net income was KRW 857,691.3 million compared to KRW 798,056.21 million a year ago.

Basic earnings per share from continuing operations was KRW 12,051 compared to KRW 11,442 a year ago. Diluted earnings per share from continuing operations was KRW 12,051 compared to KRW 11,432 a year ago. Basic earnings per share was KRW 12,051 compared to KRW 11,442 a year ago.